University of Michigan Rogel Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Michigan Rogel Cancer Center sits in the top decile of US sponsors by registered trial count (#118 of 15,742 sponsors by registered trial count).
University of Michigan Rogel Cancer Center: 292 sponsored US clinical trials, 45 recruiting.
University of Michigan Rogel Cancer Center sponsors 292 registered US clinical trials on ClinicalTrials.gov, 45 of them currently recruiting, and 167 completed. 4 of these trials are in Phase 3-4 (later-stage) and 182 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 12 trials.
Top-decile sponsor footprint
University of Michigan Rogel Cancer Center ranks in the top decile of sponsors by registered trial count (#118 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
167 of 229 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
292 total, page 1 of 6
Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma
NCT07630155
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
NCT07532525
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
NCT06914479
A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial
NCT07443943
Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)
NCT06641310
A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment
NCT07365007
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT06616155
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
NCT07158021
A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients
NCT07291414
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
NCT07094685
Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation
NCT06784336
Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes
NCT06927947
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
NCT07132645
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
NCT06866262
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer
NCT06356155
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
NCT07121595
Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors
NCT06941324
Pilot Investigation of Dual Energy CT Imaging on an Online Adaptive Radiation Therapy System
NCT07219134
Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma
NCT06580054
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
NCT07096999
CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer
NCT06915168
Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients
NCT06539468
Gilteritinib for the Treatment of ALK NSCLC
NCT06225427
Breast Cancer Resiliency Through Exercise Program (B-REP)
NCT06100263
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
NCT05988918
Living Well With Lymphoma
NCT06047626
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer
NCT05996107
A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
NCT05901519
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
NCT05956041
Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic Probe
NCT05965180
Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation
NCT05945121
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
NCT05866302
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
NCT05894083
Localized Leiomyosarcoma Biomarker Protocol
NCT04925089
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
NCT04858256
Metastatic Leiomyosarcoma Biomarker Protocol
NCT05653388
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
NCT05183126
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
NCT05038332
Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
NCT04396808
Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.
NCT04518748
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
NCT00843375
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
NCT03099356
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
NCT02763033
Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer
NCT07645391
Quantitative MRI for Myelofibrosis
NCT01973881
Feasibility of Virtual, Tailored, Music-Based Relaxation for Anxiety in Adolescent and Young Adult Cancer Survivors
NCT05911269
Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
NCT06234748
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
NCT04748042
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
NCT04848337
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
NCT04194554
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 56 |
| Phase 2 | 126 |
| Phase 3 | 2 |
| Phase 4 | 2 |
What is open in the University of Michigan Rogel Cancer Center pipeline
45 recruiting of 292 indexed (15% open); 167 completed (57%).
Phase mix: 4 late (III/IV) vs 182 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Michigan Rogel Cancer Center: open-pipeline peers nationwide
Peers matched on 292 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Michigan Rogel Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 292 trials (± recruiting share)
- Thomas Jefferson University · 292 trials · 18% recruiting
- University of Missouri-Columbia · 291 trials · 19% recruiting
- Kaiser Permanente · 294 trials · 7% recruiting
- Eisai · 287 trials · 2% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Nationwide Children's Hospital · 15% recruiting · 188 trials
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
- Bronx VA Medical Center · 15% recruiting · 13 trials
Related
What to do with this University of Michigan Rogel Cancer Center page
292 registered trials is a research-attention snapshot, not an endorsement of University of Michigan Rogel Cancer Center or any single study.
- 45 of University of Michigan Rogel Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of Michigan Rogel Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Michigan Rogel Cancer Center pipeline card: 292 registered trials from official public datasets.Report a data error.